Physician profile
Robert Wauters
NPI 1578902565
$1,591.44
in general payments reported to CMS, 2019-2025
15 companies · $985 in 2025
The $985 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.02 · 2023: $179 · 2024: $387 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,314 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,314.18 |
| Education | $236.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $430.64 | 2024-2025 | |
| Genzyme Corporation | $218.64 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $193.99 | 2024-2025 | |
| Pharming Healthcare, INC. | $123.64 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $118.19 | 2024-2025 | Dupixent |
| Genentech USA, INC. | $97.09 | 2024 | Xolair |
| Astrazeneca Pharmaceuticals LP | $71.34 | 2023-2025 | Fasenra, Airsupra |
| Ars Pharmaceuticals Operations, INC. | $66.01 | 2025 | Neffy |
| Csl Behring | $58.92 | 2022-2024 | Haegarda |
| Grifols USA, LLC | $43.68 | 2023 | Prolastin-C Liquid |
| Galderma Laboratories, L.P. | $42.97 | 2025 | Nemluvio |
| Biocryst US Sales Co., LLC | $39.00 | 2022-2023 | Orladeyo |
| Glaxosmithkline, LLC. | $35.50 | 2023-2025 | Nucala |
| Amgen INC. | $34.00 | 2025 | |
| Idorsia Pharmaceuticals US INC | $17.83 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wauters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.